DOXORUBICIN AND DOXORUBICINOL - INTRAINDIVIDUAL AND INTERINDIVIDUAL VARIATIONS OF PHARMACOKINETIC PARAMETERS

被引:47
作者
JACQUET, JM
BRESSOLLE, F
GALTIER, M
BOURRIER, M
DONADIO, D
JOURDAN, J
ROSSI, JF
机构
[1] CTR HOSP REG & UNIV NIMES,PHARMACOCINET LAB,AVE PR DEBRE,F-30006 NIMES,FRANCE
[2] FAC PHARM MONTPELLIER,DEPT PHARMACOCINET,MONTPELLIER,FRANCE
[3] HOP LAPEYRONIE,SERV MALAD SANG,MONTPELLIER,FRANCE
[4] INST CANC RES,CLIN VAL DAURELLE,MONTPELLIER,FRANCE
[5] INSERM,F-34100 MONTPELLIER,FRANCE
[6] UNIV MONTPELLIER,FAC MED,THERAPEUT LAB,MONTPELLIER,FRANCE
关键词
D O I
10.1007/BF00685716
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Doxorubicin was given by short i. v. infusion (dose range 25-72 mg/m2) to 18 patients who underwent three to seven successive courses of chemotherapy (total, 57 courses). Plasma levels of doxorubicin and its major metabolite doxorubicinol were determined by high-performance liquid chromatography over a 48-h period after the infusion. Pharmacokinetic parameters for the parent drug and its metabolite were calculated for each course of treatment. The results show considerable inter-and intraindividual variations for most parameters. The coefficients of variation (CV) ranged from 37% to 93% (inter-individual) and from 6% to 59% (intra-individual). Nevertheless, we observed a good stability over successive courses for terminal half-life in six patients (CV, 6%-25%) and for clearance and AUC in four subjects (CV, 10%-22%). The ratio of the AUCs for doxorubicinol: doxorubicin averaged 0.514. The pharmacokinetic pattern of doxorubicinol was biphasic in plasma of the majority of patients. We propose a model for curve-fitting of these metabolite plasma concentrations that is based on two successive releases of the compound in the plasma compartment, separated by a lag time. © 1990 Springer-Verlag.
引用
收藏
页码:219 / 225
页数:7
相关论文
共 28 条
[1]  
BENJAMIN RS, 1977, CANCER RES, V37, P1416
[2]  
BRENNER DE, 1984, CANCER TREAT S, V3, P77
[3]  
CHAN KK, 1978, CANCER TREAT REP, V62, P1161
[4]  
CHAN KK, 1980, CANCER RES, V40, P1263
[5]   THE PHARMACOKINETICS OF ADRIAMYCIN AND ADRIAMYCIN-METABOLITES [J].
EHNINGER, G ;
STOCKER, HJ ;
PROKSCH, B ;
WILMS, K .
KLINISCHE WOCHENSCHRIFT, 1980, 58 (18) :927-934
[6]   COMPARATIVE PHARMACOKINETIC STUDY OF ADRIAMYCIN AND 4'EPI-ADRIAMYCIN AFTER THEIR SIMULTANEOUS INTRAVENOUS ADMINISTRATION [J].
EKSBORG, S ;
STENDAHL, U ;
LONROTH, U .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1986, 30 (05) :629-631
[7]   PHARMACOKINETIC STUDY OF IV-INFUSIONS OF ADRIAMYCIN [J].
EKSBORG, S ;
STRANDLER, HS ;
EDSMYR, F ;
NASLUND, I ;
TAHVANAINEN, P .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1985, 28 (02) :205-212
[8]  
EKSBORG S, 1985, MED ONCOL TUMOR PHAR, V2, P47
[9]   PHARMACOKINETICS OF DOXORUBICIN IN MAN - DOSE AND SCHEDULE DEPENDENCE [J].
ERTTMANN, R ;
ERB, N ;
STEINHOFF, A ;
LANDBECK, G .
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 1988, 114 (05) :509-513
[10]  
EVANS WE, 1980, P ASS CANCER RES, V21, pA176